A phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of ZD6474 (Vandetanib) in combination with FOLFOX [oxaliplatin + fluorouracil + folinic acid] vs FOLFOX alone for the treatment of colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine regimen.

Trial Profile

A phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of ZD6474 (Vandetanib) in combination with FOLFOX [oxaliplatin + fluorouracil + folinic acid] vs FOLFOX alone for the treatment of colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Vandetanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 20 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2017 This trial has been completed in Spain, according to European Clinical Trials Database.
    • 25 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top